ProCE Banner Activity

Optimizing the Timing and Sequencing of Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer

Podcast Episodes
Listen to Joleen Hubbard, MD, and John L. Marshall, MD, discuss the use of key later-line treatment options for patients with mCRC, including optimal treatment sequencing and dosing and key adverse events.

Released: April 29, 2021

Expiration: April 28, 2022

Share

Faculty

Joleen Hubbard

Joleen Hubbard, MD

Associate Professor
Gastrointestinal Oncologist
Medical Oncology
Mayo Clinic
Rochester, Minnesota

John L. Marshall

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Supporters

Supported by an educational grant from

Bayer Healthcare Pharma

Faculty Disclosure

Primary Author

Joleen Hubbard, MD

Associate Professor
Gastrointestinal Oncologist
Medical Oncology
Mayo Clinic
Rochester, Minnesota

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC